Cancer is a disease of mutations.

Genomics is changing the way we diagnose, understand, and treat cancer. SearchLight DNA™ uses the power of genomics to identify clinically important cancer mutations in our pets.

Sammy

mast cell tumor
mutations in KIT, MDR1, and VEGFR2

Daisy

lymphoma
mutations in TRAF3 and PTEN

Bob

oral melanoma
mutations in KIT, MDM2, and NRAS

Luna

histiocytic sarcoma
mutations in PTPN11 and TP53

Sanford

lung adenocarcinoma
mutation in HER2

What does SearchLight DNA™ do?

By finding mutations in the DNA of your pet’s cancer cells, Vidium's SearchLight DNA™ can guide your veterinary team in understanding a cancer’s origin, its behavior, and the optimal approach to its treatment.

Many cancers are recognizable to the trained pathologists and oncologists who diagnose and treat them.

But not all cancers. Sometimes the mutations in a cancer can guide diagnosis, which is a key part of understanding what that tumor will do in the body. Some mutations only occur in specific cancer types or sub-types and so they can aid the veterinary team in identifying the cancer types.

Many mutations have been associated with a better or worse prognosis.

Thinking about the future and what comes next may be the scariest aspect of cancer in our pets. Knowing as much as we can about a cancer’s potential behavior is critically important for guiding pet families and veterinarians as they work together to generate the very best plan for that particular cancer in that particular patient and that specific family.

The whole point of understanding cancer is understanding how to stop it.

In human oncology, hundreds of safe and effective “precision therapies” exist that are directed against a cancer’s specific mutations. Fewer precision therapies exist in veterinary medicine, but as we better understand therapeutic targets in pet cancers, we believe that these therapies will become increasingly available. In some cases, we can use human drugs that are available today.

How Does SearchLight DNA™ Work?

From a sample of the pet's tumor, we use custom next-generation sequencing technology and our proprietary genomic knowledge database built on clinical and scientific publications to generate a report for the veterinarian. The report clearly describes all the mutations found in the dog's tumor, it summarizes what's currently known about the association of those mutations with cancer diagnosis, prognosis, and treatment, and it identifies relevant clinical trials.

  • Cancer Patient

    Pet with suspected cancer visits the veterinarian.

  • Veterinary Team

    The veterinary team performs a biopsy to collect a sample of the tumor. The sample is sent to Vidium or is sent to a pathologist and then sent to Vidium.

  • Vidium Animal Health

    Vidium performs tumor DNA sequencing and analysis with SearchLight DNA™, annotating the tumor mutations with biomarker data from its knowledge database.

  • Reports

    Vidium provides a detailed report to the veterinary team with information about the tumor’s mutations and their associations with diagnosis, prognosis, and treatment.

What does the Report reveal?

The Most Relevant Alterations in the Tumor’s DNA

Using next-generation sequencing of 120 cancer-associated genes selected based on the latest scientific literature and databases, SearchLight DNA™ provides the clinical team and pet family with confidence that if a mutation with clinical value is present, we've found it. These mutations can inform diagnosis, prognosis, and treatment planning.

Easily Understandable Summaries of What We Know About These Mutations

Vidium scientists have assembled the latest published data in human and veterinary studies to provide the most up-to-date knowledge database possible. We deliver that information to the healthcare team in a digestible, but complete and well-referenced format.

Targeted Therapies

Using data from veterinary and human oncology, SearchLight DNA™ provides information on therapies that may be indicated by mutations in a pet's tumor. It also provides a summary of the scientific evidence associated with those indications.

Clinical Trials

Leveraging the AVMA's Clinical Trials Database alongside supplemental curation of trials at academic centers and through industry sponsors, Vidium provides the healthcare team with up-to-date information on additional options for pets with cancer.

Who’s ready for the future of Pet Cancer Treatment and Prevention?

Join with Vidium and help us deliver a new level of precision veterinary medicine.

Get Started

Life saving statistics.

6 Million

More dogs (6 million) than humans (1.8 million) will be diagnosed with cancer this year in the United States.

94%

Around 94% of the canine genome is arranged analogously to the human [genome].

1 in 4

1 in 4 dogs will be diagnosed with cancer during their lifetime.

50%

50% of dogs over the age of 10 develop cancer at some point.

80%

Osteosarcoma accounts for some 80% of the primary bone cancers found in dogs and is one of the most common cancer types in canines.

47%

According to The Veterinary Cancer Society, cancer is the leading cause of death in 47% of dogs, especially dogs over age ten.

20%

Lymphoma is one of the most common cancers seen in dogs, accounting for 20% of all canine cancers

SearchLight DNA™ is here to help veterinarians and pet owners by bringing the best of human medicine to veterinary care.

For Veterinarians

Vidium stands ready to help veterinary teams move into the world of personalized, precision medicine. We recognize that SearchLight DNA™ is not for every cancer case, but if there is a chance that better understanding of a cancer's mutations might lead to a better treatment plan with a higher chance of efficacy and fewer side effects, we want to make that possible for you, your patients and their owners.

Tell me more

For Pet Owners

Cancer is scary. After a cancer diagnosis in our pets, we often feel lost and alone. Vidium’s mission is to bring the incredible advances happening in human oncology precision medicine to our beloved pets. Starting with our formative relationship with the Translational Genomics Research Institute (TGen, an affiliate of City of Hope), a leader at the cutting edge of precision medicine, building on our discoveries in canine cancer genetics, and continuing with our rigorous scientific validation of diagnostic assays. Talk to your veterinary team about whether SearchLight DNA™ is a good option for your pet.

Tell me more

That little bump on Bridger’s side looked pretty benign, but we were going to the vet for our annual visit, so we asked her to check it out. It turned out to be a mast cell tumor, and by performing SearchLight™ DNA, we found that it had the mutation that is targeted by Palladia™, which made the cost of therapy much easier to justify.

Claudia & Bridger Mast Cell Tumor
KIT ITD Mutations

I found Rudy as a stray with an egg sized tumor under his right leg, which turned out to be testicular seminoma. After surgery to “debulk” the tumors, we consulted an oncologist who was unable to find any literature documenting testicular seminoma in dogs, let alone successful treatment of such a case. Thankfully I found out about Vidium! They were able to analyze his tumor and identify the driver mutations specific to Rudy’s case to determine which chemotherapy drugs would be most effective. The (Vidium) team was so genuine in their concern for Rudy and I, and very responsive to my questions. Today, Rudy is cancer free and living his best life!

Stefanie & Rudy Testicular Seminoma

He’s an important part of our family. When we found out the little bump on his side was more than just a bump, we wanted to understand as much as we could in order to better fight that disease. SearchLight DNA™ and Vidium helped guide us through the cancer journey, and our oncologist made sure we did everything we could.

Samantha & Tee-Tee Mutations in KIT and TP53

When what we thought was a sore in his mouth ended up being cancer, and an aggressive carcinoma to boot, we were devastated. We even got more concerned when we Googled information about dogs who had the same type of tumor as Barley. But our long-time veterinarian referred us to a great oncologist who took a diagnostic sample and sent it to Vidium for SearchLight DNA™ testing, and we found out there are a couple of human drugs that target the mutations they found in Barley’s tumor, which we are all in to try.

Mark and Barley Oral Squamous Cell Carcinoma
V450E BRAF Mutation

Rusty has one of the most frightening kinds of cancer a dog can get. Our veterinary oncologist knew how hard we would take the news, and she levelled with us, but in a very empathetic way. She said that there was no sugar-coating how hard it was to treat this type of cancer in a dog but sending a sample of the tumor for SearchLight DNA™ analysis would provide the best opportunity for matching to potential therapies based on the genetic mutations associated with Rusty’s cancer. We are fully aware that this is an uphill battle, but we and Rusty are going to put up a fight.

Diane and Rusty Osteosarcoma
SETD2 and DMD Mutations

I have a cousin who was diagnosed with melanoma, but I never knew dogs could get it until we got the news about April. Fortunately, our veterinarian also shared news about a cutting-edge analysis called SearchLight DNA™ that identifies mutations in the tumor that help explain treatments that might have a better chance of success. We met with our veterinarian last week and we are going to get April on a therapy that has shown promise in treating dogs with the same mutation as April has. So, we’re hopeful.

Robert and April RAS Mutations
Canine Malignant Melanoma

Backed by TGen

The Translational Genomics Research Institute (TGen, an Affiliate of City of Hope) is a leader in the genomics revolution. Begun by Dr. Jeffrey M. Trent, the founding Scientific Director of the Human Genome Project, this world-class research institute explores the most advanced areas of genetics in human and animal health. As a subsidiary of TGen, Vidium Animal Health benefits from the incredible knowledge and research of TGen scientists.

Learn more